Last updated on April 23, 2014 at 1:22 EDT

Health Robotics Reports 28 New Agreements in 1Q2013, Including 18 Contracts in the United States of America

April 22, 2013

BOZEN, Sud-Tirol, Italy, April 22, 2013 /PRNewswire/ –

Health Robotics reported 28 new contracts in 1Q2013, including 12 new Robots [versus 6
Robots in 1Q2012; 8 for Oncology and 4 for non-hazardous IVs] and 16 new i.v.SOFT workflow
software agreements [versus 11 i.v.SOFT contracts in 1Q2012]. After a dominant record
overseas with almost 300 global installations outside the USA since 2007,
http://www.health-robotics.com/en/installations, Health Robotics is now also the clear
leader in the United States’ Sterile Compounding Automation sector, with 30 Robots and 50
i.v.SOFT workflow installations, only two years after directly entering the North American

Gaspar DeViedma, Health Robotics’ Executive Vice President and Board Member, stated:
“I’m very pleased with such a strong sales-kickoff for Health Robotics in the United
States this year. As predicted, Health-System pharmacists in the USA now recognize the
undeniable fact that Health Robotics’ second generation modular architecture of integrated
and networked medical devices are fully automated, offer 3 to 4 times faster
speed/throughput, for less than half the price, size, and weight than its global
competitors[1], delivering payback periods/R.O.I. of less than 1 year,

During the last quarter, Health Robotics and/or its sales channel network signed 28
new installations for either Batch and/or Patient-Specific Sterile Compounding Automation
at: Monroe Carrell Children’s Hospital at Vanderbilt University [TN], Huntsville Hospital
Health System [AL], William W. Backus Hospital [CT], Kameda Hospital [Japan], Recep Tayyip
Erdogan University Hospital [Rize, Turkey], Memorial Okmeydani Hospital [Istanbul], and
Sisli Etfal University Hospital [Istanbul], amongst others, plus the exclusive 5-year
contract with Amerinet.

About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world
[including over 90% the Oncology Robots global market], Health Robotics is the undisputed
leading supplier of life-critical intravenous medication robots, providing over 350
hospital installations in 5 continents with the only fully-integrated robotics-based
technology, IV Workflow, and manual compounding software automation solution. Health
Robotics’ second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have
been found [through scientific and peer-reviewed studies[2],[3]] to greatly contribute to
ease hospitals’ growing pressures to improve patient safety[2], increase throughput, and
contain costs[2]. Through the effective and efficient production of sterile, accurate,
tamper-evident and ready-to-administer IVs, Health Robotics’ medical devices and
integrated workflow solutions help hospitals eliminate life-threatening drug[2] and
diluent[2] exchange errors, improve drug potency[3], decrease other medical mistakes and
sterility risks, work more efficiently[2], reduce waste and controlled substances’
diversion, and diminish the gap between rising patient volume/acuity and scarce nursing,
and pharmacy staff. For more information, please visit: http://www.health-robotics.com


1. Competitors: Intelligent Hospital Systems/RIVA, Fresenius Kabi/MDS, Baxter/Baxa,
and Loccioni.

2. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger,
Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and
Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard
Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

3. Validation of an automated method for compounding monoclonal antibody patient
doses: case studies of Avastin(R), Remicade(R), and Herceptin(R). Peters, Capelle,
Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

        For additional information, please contact:
        Phone +1-786-417-1251

SOURCE Health Robotics

Source: PR Newswire